已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Atorvastatin for Anthracycline-Associated Cardiac Dysfunction

医学 蒽环类 阿托伐他汀 射血分数 内科学 随机对照试验 化疗 队列 回顾性队列研究 心力衰竭 癌症 乳腺癌
作者
Tomas G. Neilan,Thiago Quinaglia,Takeshi Onoue,Syed Mahmood,Zsófia D. Drobni,Hannah Gilman,Amanda M. Smith,Julius C. Heemelaar,Priya Brahmbhatt,Jor Sam Ho,Supraja Sama,Jakub Svoboda,Donna Neuberg,Jeremy S. Abramson,Ephraim P. Hochberg,Jefferey A. Barnes,Philippe Armand,Eric D. Jacobsen,Caron A. Jacobson,Austin I. Kim
出处
期刊:JAMA [American Medical Association]
卷期号:330 (6): 528-528 被引量:84
标识
DOI:10.1001/jama.2023.11887
摘要

Importance Anthracyclines treat a broad range of cancers. Basic and retrospective clinical data have suggested that use of atorvastatin may be associated with a reduction in cardiac dysfunction due to anthracycline use. Objective To test whether atorvastatin is associated with a reduction in the proportion of patients with lymphoma receiving anthracyclines who develop cardiac dysfunction. Design, Setting, and Participants Double-blind randomized clinical trial conducted at 9 academic medical centers in the US and Canada among 300 patients with lymphoma who were scheduled to receive anthracycline-based chemotherapy. Enrollment occurred between January 25, 2017, and September 10, 2021, with final follow-up on October 10, 2022. Interventions Participants were randomized to receive atorvastatin, 40 mg/d (n = 150), or placebo (n = 150) for 12 months. Main Outcomes and Measures The primary outcome was the proportion of participants with an absolute decline in left ventricular ejection fraction (LVEF) of ≥10% from prior to chemotherapy to a final value of <55% over 12 months. A secondary outcome was the proportion of participants with an absolute decline in LVEF of ≥5% from prior to chemotherapy to a final value of <55% over 12 months. Results Of the 300 participants randomized (mean age, 50 [SD, 17] years; 142 women [47%]), 286 (95%) completed the trial. Among the entire cohort, the baseline mean LVEF was 63% (SD, 4.6%) and the follow-up LVEF was 58% (SD, 5.7%). Study drug adherence was noted in 91% of participants. At 12-month follow-up, 46 (15%) had a decline in LVEF of 10% or greater from prior to chemotherapy to a final value of less than 55%. The incidence of the primary end point was 9% (13/150) in the atorvastatin group and 22% (33/150) in the placebo group ( P = .002). The odds of a 10% or greater decline in LVEF to a final value of less than 55% after anthracycline treatment was almost 3 times greater for participants randomized to placebo compared with those randomized to atorvastatin (odds ratio, 2.9; 95% CI, 1.4-6.4). Compared with placebo, atorvastatin also reduced the incidence of the secondary end point (13% vs 29%; P = .001). There were 13 adjudicated heart failure events (4%) over 24 months of follow-up. There was no difference in the rates of incident heart failure between study groups (3% with atorvastatin, 6% with placebo; P = .26). The number of serious related adverse events was low and similar between groups. Conclusions and Relevance Among patients with lymphoma treated with anthracycline-based chemotherapy, atorvastatin reduced the incidence of cardiac dysfunction. This finding may support the use of atorvastatin in patients with lymphoma at high risk of cardiac dysfunction due to anthracycline use. Trial Registration ClinicalTrials.gov Identifier: NCT02943590
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
TIANNANXING完成签到,获得积分10
2秒前
耷拉地啦完成签到,获得积分10
9秒前
初昀杭完成签到 ,获得积分10
14秒前
晓书完成签到 ,获得积分10
15秒前
22秒前
Ultraman45发布了新的文献求助10
22秒前
JamesPei应助林佳一采纳,获得10
23秒前
科研小白完成签到 ,获得积分10
23秒前
正直蜗牛完成签到,获得积分10
23秒前
Akim应助白日梦采纳,获得10
24秒前
26秒前
小澜孩完成签到,获得积分10
26秒前
小澜孩发布了新的文献求助10
29秒前
33秒前
科目三应助彼岸花开采纳,获得50
34秒前
36秒前
白日梦发布了新的文献求助10
40秒前
cy0824完成签到 ,获得积分10
42秒前
Omni完成签到,获得积分10
45秒前
胡图图啦啦完成签到 ,获得积分10
47秒前
白日梦完成签到,获得积分10
47秒前
斜阳完成签到 ,获得积分10
51秒前
2333完成签到 ,获得积分10
51秒前
量子星尘发布了新的文献求助10
56秒前
爆米花应助懂得瞧采纳,获得10
58秒前
mini完成签到 ,获得积分10
59秒前
健壮惋清完成签到 ,获得积分10
1分钟前
机灵的听云完成签到,获得积分20
1分钟前
xiao完成签到 ,获得积分10
1分钟前
鹿靡完成签到,获得积分10
1分钟前
挤爆沙丁鱼完成签到,获得积分10
1分钟前
lf发布了新的文献求助10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
科研通AI5应助科研通管家采纳,获得10
1分钟前
完美世界应助科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
mmyhn完成签到,获得积分10
1分钟前
懂得瞧发布了新的文献求助10
1分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976600
求助须知:如何正确求助?哪些是违规求助? 3520689
关于积分的说明 11204470
捐赠科研通 3257316
什么是DOI,文献DOI怎么找? 1798683
邀请新用户注册赠送积分活动 877881
科研通“疑难数据库(出版商)”最低求助积分说明 806613